Whole-exome sequencing reveals somatic mutations and therapeutic targets in breast cancer, highlighting precision oncology potential in MENA populations.
Key Points
Characterize somatic mutations and therapeutic opportunities for breast cancer in MENA populations.
Performed whole-exome sequencing on 52 breast cancer samples, including 51 from the MENA region.
Identified somatic variants and predicted driver mutations using COSMIC database and tools like BoostDM and OncodriveMUT.
Conducted mutational signature analysis to determine patterns in Luminal A tumors.
Detected 37,369 somatic variants and identified 2451 predicted driver mutations, including known drivers like TP53 and PIK3CA.
Found novel predicted drivers impacting DNA repair pathways such as BRCA2 and MLH1.
Highlighted 223 actionable mutations for precision oncology.